Yokneam-based Syneron Medical today announced that a US federal judge on Friday dismissed a motion by Lumenis (Nasdaq: LUME) requesting a temporary restraining order against Syneron.
“We are extremely pleased with the decision of the courts and we have always known that the Aurora family of products are superior and unique technologies,” said Moshe Mizrahy, CEO of Syneron Medical. “Syneron will continue to communicate to the market and to each customer the superiority of its proprietary, patented and patent-pending Electro-Optic Synergy (ELOS) technology.”
Mizrahy continued, “From the very beginning, we have always felt that the marketplace would decide which company has the better technology, not the courts. It is unfortunate that Lumenis continues to feel compelled to use the court to decide these matters. Syneron intends to vigorously defend and protect its good name and its interests and will consider all of its options at the appropriate time.”
Syneron received US Food and Drug Administration (FDA) clearance to market the Aurora DS system for hair removal in July 2002, and the Aurora SR for the treatment of superficial, benign vascular and pigmented lesions (skin renewal) in October 2002.
In a lawsuit filed October 28 in United States District Court for the Central District of California, Lumenis sued Syneron Medical Ltd, Syneron Inc., Syneron Canada Corp. and 10 unknown defendants for infringement of the company's US patents. The suit sought unspecified damages as well as “a preliminary and permanent injunction against the continued infringement of these patents”.
Published by Globes [online] - www.globes.co.il - on 3 November, 2002